Selective prevention of mechanical hyperalgesia after incision by spinal ERK1/2 inhibition

被引:16
|
作者
van den Heuvel, I. [1 ]
Reichl, S. [2 ]
Segelcke, D. [2 ]
Zahn, P. K. [3 ]
Pogatzki-Zahn, E. M. [2 ]
机构
[1] Univ Childrens Hosp Muenster, Dept Gen Pediat, Munster, Germany
[2] Univ Hosp Muenster, Dept Anesthesiol Intens Care Med & Pain Therapy, Munster, Germany
[3] Ruhr Univ Bochum, Berufsgenossenschaftl Univ Klinikum Bergmannsheil, Dept Anesthesiol Intens Care Med Palliat Care Med, Bochum, Germany
关键词
SIGNAL-REGULATED KINASE; ACTIVATED PROTEIN-KINASE; DORSAL-HORN NEURONS; ACID RECEPTOR ANTAGONISTS; PRIMARY AFFERENT NEURONS; NERVE LIGATION; MAP KINASE; RAT MODEL; DIFFERENTIAL ACTIVATION; GLIAL ACTIVATION;
D O I
10.1002/ejp.540
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
BackgroundActivation of extracellular signal-regulated kinases (ERK1/2) has been shown to play an important role in several pain states. Here we investigated the ERK1/2 contribution to non-evoked and evoked pain-like behaviour in rats after surgical incision. MethodsSpinal phosphorylation of ERK1 and ERK2 was assessed 15min, 4h, 24h and 5 days after plantar incision and sham incision. The effect of PD98059, a specific inhibitor of ERK1/2 activation, administered intrathecally (IT) 1h before or 2h after incision on spinal ERK1 and ERK2 phosphorylation was assessed. In behavioural experiments, the effect of PD98059 administered 1h before or after incision on non-evoked pain behaviour and mechanical and heat hyperalgesia was assessed. ResultsPhosphorylated ERK1 and ERK2 were rapidly increased in the ipsilateral dorsal horn from rats after incision post-operatively. This increased ERK1 and ERK2 phosphorylation were blocked by PD98059 administered before incision. In congruence, IT administration of PD98059 before incision delayed mechanical hyperalgesia after incision; however, administration after incision had only a modest effect on mechanical hyperalgesia. In addition, PD98059 did not affect non-evoked pain behaviour or heat hyperalgesia after incision. ConclusionThe results suggest that spinal ERK1 and ERK2 are involved in regulation of pain after incision differentially with regard to the pain modality. Furthermore, blockade of ERK1/2 activation was most effective in a preventive manner, a condition which is rare after incision. Spinal ERK1/2 inhibition could therefore be a very useful tool to manage selectively movement-evoked pain after surgery in the future.
引用
收藏
页码:225 / 235
页数:11
相关论文
共 50 条
  • [41] Inhibition of cerebrovascular ERK1/2 activation reduces late cerebral ischemia and receptor upregulation after subarachnoid hemorrhage
    Ansar, S.
    Edvinsson, L.
    HYPERTENSION, 2007, 50 (04) : 801 - 801
  • [42] Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
    Ren, Li
    Grina, Jonas
    Moreno, David
    Blake, James F.
    Gaudino, John J.
    Garrey, Rustam
    Metcalf, Andrew T.
    Burkard, Michael
    Martinson, Matthew
    Rasor, Kevin
    Chen, Huifen
    Dean, Brian
    Gould, Stephen E.
    Pacheco, Patricia
    Shahidi-Latham, Sheerin
    Yin, Jianping
    West, Kristina
    Wang, Weiru
    Moffat, John G.
    Schwarz, Jacob B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) : 1976 - 1991
  • [43] Prolongation of cardiac allograft survival by inhibition of ERK1/2 signaling in a mouse model
    Wang, Shuang
    Guan, Qiunong
    Diao, Hong
    Lian, Dameng
    Zhong, Robert
    Jevnikar, Anthony M.
    Du, Caigan
    TRANSPLANTATION, 2007, 83 (03) : 323 - 332
  • [44] Selective interference with nuclear ERK1/2 signaling prevents pathological cardiac hypertrophy
    Ruppert, C.
    Vidal, M.
    Lohse, M. J.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S68 - S68
  • [45] Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury
    Sabbatini, M
    Santillo, M
    Pisani, A
    Paternò, R
    Uccello, F
    Serù, R
    Matrone, G
    Spagnuolo, G
    Andreucci, M
    Serio, V
    Esposito, P
    Cianciaruso, B
    Fuiano, G
    Avvedimento, EV
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 290 (06) : F1408 - F1415
  • [46] A highly selective Erk1/2 Inhibitor with in-vivo anti tumor potency
    Seipelt, Irene
    Guenther, Eckhard
    Blumenstein, Lars
    Mueller, Gilbert
    Schmidt, Peter
    Aicher, Babette
    Teifel, Michael
    Gerlach, Matthias
    CANCER RESEARCH, 2011, 71
  • [47] Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor
    Flemington, Vikki
    Simpson, Iain
    Davies, Emma
    Robinson, David
    Lindsay, Nicola
    Hanson, Lyndsey
    Hopcroft, Philip
    Tonge, Michael
    Roberts, Karen
    Ward, Richard
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [48] Anti-angiogenic Potential of Scopoletin is Associated With the Inhibition of ERK1/2 Activation
    Pan, Rong
    Dai, Yue
    Yang, Jian
    Li, Ying
    Yao, Xiujuan
    Xia, Yufeng
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (03) : 214 - 219
  • [49] ERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism
    Mclean, Erin
    De Roo, Caroline
    Maag, Annabel
    Coble, Megan
    Cano, Jefferson
    Liu, Ruijie
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2025, 30 (01):
  • [50] ERK1/2 inhibition overcomes resistance to venetoclax in AML by altering mitochondrial metabolism
    Sharma, Priyanka
    Ostermann, Lauren
    Piya, Sujan
    Baran, Natalia
    Tyagi, Anudishi
    Hindley, Christopher
    Dao, Kim-Hien
    Sims, Martin
    Battula, V. Lokesh
    Andreeff, Michael
    Borthakur, Gautam
    CANCER RESEARCH, 2023, 83 (07)